In July, the six viral marker assay conversion at CTS Dallas, Phoenix and Tampa laboratories was achieved with minimal disruption and substantial cost saving to our healthcare partners.
CTS Tampa lab implemented the Ortho Clinical Diagnostics VITROS® testing platform to perform COVID-1...
In August CTS begins source plasma testing as a new line of business to one of the largest plasma fr...
In January, CTS is incorporated as a non-profit organization owned by Vitalant and OneBlood (formerl...
CTS embraces a company-wide operational excellence initiative designed to change the culture to enha...
In 2016, CTS tested more source plasma samples (4.9 million) than blood donor samples (4.5 million).
In October, due to demand from existing healthcare partners, CTS began testing blood donors for anti...